Credit Suisse’s Exagen XGN Stock Holding History

Credit Suisse’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$12K	–	3761
2022 Q4	$12K	Buy	+5,000	New	+$12.8K	﹤0.01%	3501
2022 Q3	–	Sell	-5	Closed	–	–	4337
2022 Q2	$0	Buy	+5	New	+$29	﹤0.01%	4366

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's XGN Position: Q1 2023 in Review

Credit Suisse sold out of Exagen (XGN) in Q1 2023, closing a stake of 5,000 shares — an estimated $12K sold.

Credit Suisse first reported a position in XGN in Q2 2022 and held it in 2 quarters. The position peaked at $12K in Q4 2022. 28 funds tracked by Wall St. Rank hold XGN as of Q1 2023.

Credit Suisse reported no remaining Exagen position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 5,000 Exagen shares in Q1 2023, an estimated $12K.
Credit Suisse first reported a position in Exagen in Q2 2022 and held it in 2 quarters.
Credit Suisse's Exagen position peaked at $12K in Q4 2022.
28 funds tracked by Wall St. Rank held Exagen as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.